Drugs / BI 1821736
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05839600 | Jun 2023 → Apr 2025 | cancer | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1821736 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05839600 ↗ |
| Modality | Other / unclassified | “BI 1821736 is a type of immunotherapy. It is a special virus that kills cancer cells and helps the immune system fight cancer.” NCT05839600 ↗ |
| Route | Intravenous | “BI 1821736 is given to humans for the first time. Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3 months.” NCT05839600 ↗ |